Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.
Imaji M, Fujimoto D, Sato Y, Sakata Y, Oya Y, Tamiya M, Suzuki H, Ikeda H, Kijima T, Matsumoto H, Kanazu M, Hino A, Inaba M, Tsukita Y, Arai D, Maruyama H, Hara S, Tsumura S, Kobe H, Sumikawa H, Sakata S, Yamamoto N. Imaji M, et al. Among authors: ikeda h. Eur J Cancer. 2023 Jan;179:15-24. doi: 10.1016/j.ejca.2022.10.029. Epub 2022 Nov 12. Eur J Cancer. 2023. PMID: 36470023
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: ikeda h. Lung Cancer. 2023 Dec;186:107426. doi: 10.1016/j.lungcan.2023.107426. Epub 2023 Nov 19. Lung Cancer. 2023. PMID: 37992594
Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: ikeda h. Lung Cancer. 2024 Feb;188:107450. doi: 10.1016/j.lungcan.2023.107450. Epub 2023 Dec 30. Lung Cancer. 2024. PMID: 38160082 No abstract available.
[Pulmonary nocardiosis--statistical analysis in Japan].
Kaneko T, Matsumoto H, Ikeda H, Ito A, Okubo T. Kaneko T, et al. Among authors: ikeda h. Kansenshogaku Zasshi. 1987 May;61(5):606-14. doi: 10.11150/kansenshogakuzasshi1970.61.606. Kansenshogaku Zasshi. 1987. PMID: 3117948 Japanese. No abstract available.
Associations between day-by-day variability in blood pressure measured at home and antihypertensive drugs: the J-HOME-Morning study.
Ishikura K, Obara T, Kato T, Kikuya M, Shibamiya T, Shinki T, Ikeda U, Kobayashi Y, Metoki H, Mano N, Kuriyama S, Ohkubo T, Imai Y; J-HOME-Morning Study Group. Ishikura K, et al. Among authors: ikeda u. Clin Exp Hypertens. 2012;34(4):297-304. doi: 10.3109/10641963.2012.681087. Epub 2012 May 7. Clin Exp Hypertens. 2012. PMID: 22564087
Syntheses of apogalanthamine analogs as alpha-adrenergic blocking agents.
Kobayashi S, Kihara M, Shizu S, Katayama S, Ikeda H, Kitahiro K, Matsumoto H. Kobayashi S, et al. Among authors: ikeda h. Chem Pharm Bull (Tokyo). 1977 Dec;25(12):3312-23. doi: 10.1248/cpb.25.3312. Chem Pharm Bull (Tokyo). 1977. PMID: 24504 No abstract available.
4,445 results